Extension of Public Smoking Ban Was Not Associated with Any Immediate Effect on Stroke Occurrence in Finland
- PMID: 34064896
- PMCID: PMC8151542
- DOI: 10.3390/jcm10102060
Extension of Public Smoking Ban Was Not Associated with Any Immediate Effect on Stroke Occurrence in Finland
Abstract
We investigated the association between the widening of a nationwide restaurant smoking ban, enacted on 1 June 2007, and stroke admissions. All acute stroke admissions between 1 May 2005 and 30 June 2009 were retrieved from a mandatory registry covering mainland Finland. Patients aged ≥18 years were included. One annual admission per patient was included. Negative binomial regression accounting for the at-risk population was applied. We found no difference in stroke occurrence before and after the smoking ban within 7 days (p = 0.217), 30 days (p = 0.176), or the whole study period (p = 0.998). Results were comparable for all stroke subtypes (ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage). There was no sign of decreased occurrence in June 2007 compared to June in 2005-2006, and all subtypes of stroke occurred at least as frequently in both May and June of 2008 as in May and June of 2007. In conclusion, the nationwide restaurant smoking ban Finland enacted in June 2007 was not associated with any immediate reduction in stroke occurrence.
Keywords: public health; smoking; smoking ban; stroke.
Conflict of interest statement
Jussi Sipilä has received honoraria (Merck, Pfizer, Sanofi), consultancy fees (Rinnekoti Foundation, Medaffcon), travel grants, and congress sponsorship (Abbvie, Orion Pharma, Merck Serono, Sanquin, Lundbeck, Novartis) and holds shares (Orion Corporation). Jori Ruuskanen has received scientific consultancy fees (Merck, Sandoz), speaker fees (Merck, Biogen Idec, UCB Pharma, Bayer), and travel grants and congress sponsorship (BMS, Sanofi-Genzyme, TEVA, Bayer). Jussi Posti has received speaker fees (Finnish Medical Association); Päivi Rautava declares no conflict of interest; Ville Kytö has received scientific consultancy fees (AstraZeneca), speaker fees (Bayer, Boehringer-Ingelheim, Roche), and travel grants and congress sponsorship (AstraZeneca, Boehringer-Ingelheim, Bayer, Pfizer).
Figures

References
-
- Frazer K., Callinan J.E., McHugh J., van Baarsel S., Clarke A., Doherty K., Kelleher C. Legislative smoking bans for reducing harms from secondhand smoke exposure, smoking prevalence and tobacco consumption. Cochrane Database Syst. Rev. 2016;2:CD005992. doi: 10.1002/14651858.CD005992.pub3. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources